Introducing HYOGEN® with Imuvant

From the science of Ceva; a new mycoplasma vaccine against enzootic pneumonia caused by Mycoplasma hyopneumoniae

Respiratory disease is the most frequent and economically significant disease affecting swine production in Asia. Certain respiratory infections, like Mycoplasma hyopneumoniaeare present on over 90% of farms worldwide and are therefore a major threat to animal welfare.

Ceva is committed to improving pig respiratory health through the development of vaccines such as Coglapix®, Auphyl Plus® and the innovative, new HYOGEN® that prevent the development of such diseases.

HYOGEN® with ImuvantTM is a unique inactivated vaccine that offers quick strong and long lasting protection using just ONE dose. The antigen originated from Ceva M. hyo strain BA 2940-99. ImuvantTM  is a unique and innovative Ceva adjuvant composed of a non-toxic lipopolysaccharide (LPS) from J5E. coli together with a mineral oil in water emulsion. These components and balanced formulation will enable an appropriate innate, humoral and cell-mediated immune response from the piglet. In the field it translates into better protection againstM. hyopneumoniae and better productivity results.

Commenting on the introduction of the new vaccine, Dr. Ricardo Munoz, Head of Asia Ceva’s Swine business said:“HYOGEN is a further step forward Ceva’s plan, to be closer to the swine industry in Vietnam and Philippines with a differentiated and complete swine vaccine range. A range of solution that now is combined with the Ceva Lung Program, which will allow us to work together with veterinarians and producers to assist them in achieving better preventative respiratory health on their farms”.

HYOGEN® is another example of how Ceva is partnering to meet its mission: “Together, beyond animal health”.

More details about HYOGEN® please click here.

Last update: 11/04/2016

Back to top